[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$2374b
Johnson & Johnson (JNJ) shares are up after a strong Q2 earnings report, beating estimates and raising the company's outlook for the year. The stock is up X% after Q2 results beat estimates.
About $2374b
This topic is about the financial performance and social media discussion surrounding Johnson & Johnson (JNJ) stock.
Insights #
- $2374b Sentiment hit an all time of XXX for the day
- $2374b Creators hit a high of XX for the day
- $2374b Creators hit an all time of XX for the day
- $2374b Engagements hit a high of XXXXXX for the day
- $2374b Engagements hit an all time of XXXXXX for the day
- $2374b Mentions hit a high of XX for the day
- $2374b Mentions hit an all time of XX for the day
Engagements: XXX #
Engagements 24-Hour Chart Data
Current Value: XXX
Daily Average: XXXXX
6 Months: XXXXXX +7,711%
1 Year: XXXXXX -XX%
1-Year High: XXXXXX on 2025-07-16
1-Year Low: X on 2024-10-22
| Social Network | X |
|---|---|
| Engagements | XXX |
Mentions: XX #
Mentions 24-Hour Chart Data
Current Value: XX
Daily Average: X
6 Months: XX +325%
1 Year: XX +282%
1-Year High: XX on 2025-07-16
1-Year Low: X on 2024-10-05
| Social Network | X |
|---|---|
| Mentions | XX |
Creators: XX #
Creators 24-Hour Chart Data
XX unique social accounts have posts mentioning $2374b in the last XX hours which is down XX% from XX in the previous XX hours
Daily Average: X
6 Months: XX +329%
1 Year: XX +270%
1-Year High: XX on 2025-07-16
1-Year Low: X on 2024-10-05
Sentiment: XXX% #
Sentiment 24-Hour Chart Data
Current Value: XXX%
Daily Average: XXX%
1 Year: XXX% +93%
1-Year High: XXX% on 2025-07-16
1-Year Low: XXX% on 2025-07-16
Most Supportive Themes
- Positive Earnings Report for JNJ: (80%) Johnson & Johnson (JNJ) reported strong Q2 earnings, exceeding revenue and EPS estimates, leading to positive sentiment and increased stock price.
- Market Outperformance: (20%) The market is reacting positively to Johnson & Johnson's (JNJ) strong performance, with analysts and investors highlighting the company's robust revenue and earnings.
Most Critical Themes
Network engagement breakdown:
| Network | Positive | % | Neutral | % | Negative | % |
|---|---|---|---|---|---|---|
| X | XX | X% | XXX | XX% | X | X% |
| Total | XX | X% | XXX | XX% | X | X% |
Top assets mentioned In the posts about $2374b in the last XX hours
Johnson & Johnson (JNJ) Johnson & Johnson (JNJ) Advanced Micro Devices (AMD) GammaSwap (GS)
Top topics mentioned In the posts about $2374b in the last XX hours
jnj, eps, $jnj, medtech, rev, $2286b, $932b, $913b, $554b, $936b, stocks, $2284b, $2283b, $2285b, $914b, $934b, $62b, johnson johnson, $838b, $1846b, $1555b, bitfinex, $4141b, $918b, $91b, bmnr, founders fund, $85b, $338b, $354b, $181b, $165b, $amd, $1350b, $1458b, $gs, $1591b, cash flow, del, wallstreet, new york stock exchange, $931b, $927b, stockmarket
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Grayscale (Grayscale Bitcoin Trust): $21.95B$31.57B (183349263801 BTC) U.S. Government: $23.94B$25.49B (200000213000 BTC) Fidelity (FBTC): $23.74B$41.41B (198424346000 BTC) Bitfinex: $15.55B$18.46B (130010154246 BTC) Winklevoss Twins: $8.38B (70000 BTC)"
@wil12061164 on X 2025-07-18 14:48:02 UTC 3945 followers, XX engagements
"#Stock 🔥✅ REPORT $JNJ Johnson & Johnson ✅🔥 #EARNINGS 👉 EPS: $XXXX / $XXXX (expected) 👉 Revenue: $23.74B / $22.86B (expected) $JNJ: +0.67%"
@Teplitsa_ on X 2025-07-17 05:25:50 UTC XXX followers, XX engagements
"$AMD up XXXX% - Jefferies & Co increased price target from $XXX to $XXX. $BAC increase price targets from $XXX to $XXX $JNJ up XXXX% after double beat on earnings; Revenue up XXX% YoY and raising its full-year guidance EPS: $XXXX vs $XXXX Revenue: $23.74B vs $22.86B 4/9"
@EtCrypto20 on X 2025-07-17 04:12:25 UTC XX followers, XX engagements
"$JNJ announces its Q2 2025 earnings: EPS at $XXXX beating estimates by $XXXX with revenue at $23.74B (+5.77% YoY). Notably XX brands reported double-digit growth despite challenges from STELARA's biosimilar competition. 🚀 Key highlights in growth (4.6%) across diverse sectors especially Innovative Medicine and MedTech. Future prospects look solid with important product launches ahead. 📈 However watch for risks related to market competition and increased debt from acquisitions. For more details check"
@value_verge on X 2025-07-17 03:42:34 UTC XX followers, XX engagements